Mepact demonstrated a predictable, manageable tolerability profile[1,2]

When used in combination with chemotherapy, Mepact was shown to have mild to moderate side effects.[2] These were largely related to immune activation and the resulting biological activity.[1-3]

Hearing loss was the only AE that occurred at a higher frequency with Mepact in combination with chemotherapy, versus chemotherapy alone.[1]

Prescribing information

Local PI to be added in accordance with local laws and regulations

References

1. European Medicines Agency. Available at: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/000802/WC500026564.pdf. [Accessed February 2016].
2. Mepact Summary of Product Characteristics.
3. Anderson P. *Future Oncol* 2006; 2: 333-343.

Job code: GLO/MEP/2016-00001b
Date of preparation: February 2016

Takeda ONCOLOGY

Mepact® mifamurtide

Takeda ONCOLOGY

Mepact® mifamurtide

No added disruption to young lives

With a defined treatment schedule,
Mepact fits around planned chemotherapy regimens[2]

First 12 weeks

Twice weekly at least 3 days apart
Total: 24 infusions

Next 24 weeks

Once weekly
Total: 24 infusions

- Recommended dose for all patients is 2 mg/m² body surface area
- IV infusion over one hour
- Can be adjusted to fit with patient's chemotherapy schedule
- Not necessary to interrupt Mepact schedule if patient's chemotherapy is delayed
- May be administered on the same day as adjuvant combination chemotherapy

After chemotherapy, the additional 18 weeks of **Mepact can be administered as an outpatient treatment**[2]

Administration of **Mepact:** an overview[2]

It is recommended that Mepact is reconstituted in a laminar flow cabinet using sterile gloves and aseptic technique. Reconstitution will take about 30 minutes.

For full instructions on the administration of Mepact, visit **www.mepact.net**

1. Insert the spike firmly into the vial septum until seated. Do not remove the filter luer connector cap
2. Using the needle and syringe, withdraw 50 ml of sodium chloride solution from the bag
3. Attach the syringe by opening the filter luer connector cap
4. Add the sodium chloride solution into the vial
5. Leave the vial to stand undisturbed for one minute
6. With the filter and syringe still attached, shake the vial vigorously for one minute
7. Withdraw the desired dose from the vial
8. Remove the syringe, place a new needle on the suspension-filled syringe, and inject back into the bag
9. Gently swirl the bag to mix the solution
10. Infuse the suspension intravenously over 1 hour

How to use Mepact

Mepact mifamurtide